A combination of mRNA and a new lipid nanoparticle could help heal damaged lungs, according to new research from the Perelman ...

A combination of mRNA and a new lipid nanoparticle could help heal damaged lungs, according to new research from the Perelman ...

The main signs of COVID-19 are respiratory symptoms, like congestion and a cough. But COVID-19 can also cause skin rashes, ...

A Chinese biotech that became popular by co-developing an anti-Covid drug has filed for a Hong Kong stock market listing.

Immune cell populations of people with post-vaccination syndrome had lower levels of effector CD4 T cells and higher levels ...

A new study shows non-menopausal women between the ages of 40 and 54 had a significantly higher risk of developing long covid ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Regeneron settles patent lawsuit over protein for testing COVID-19 treatments December 16, 2024 AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 ...